This Core component of the Center will provide essential central shared resources to all components; these include medical, psychiatric assessment, computer, statistical, subject recruiting, pharmacy, urinalysis, secretarial, and administrative support services. These resources will permit the conduct of controlled experiments described in the other components by supporting recruitment, screening, intake, and psychiatric/behavioral characterization of study participants; medical evaluation and supervision of participants; pharmacy preparation of appropriately-blinded medications; collection of clinical outcome data (both urinalysis results and clinical interview/assessment results); management and analysis of study data; and scientific reporting of Center results. This application builds on an existing sophisticated research program that is well-experienced and productive in all of these domains. These Core resources will permit us to obtain important data concerning how best to implement LAAM pharmacotherapy of opioid abuse and concerning the effective implementation of structured behavioral therapies for drug abuse. The studies will be conducted in three sites -- a well-controlled residential human laboratory, an outpatient clinical pharmacology treatment research clinic, and a community drug abuse treatment clinic. At all sites the psychiatric assessment staff will provide careful psychiatric diagnostic and behavioral screening and characterization of the participants. These assessment data will be used to stratify the randomization of participants in the clinical trials and to identify patient characteristics associated with variations in outcome. Of greatest interest will be comparisons of patients with and without antisocial personality disorder and the possibility of their differential response to treatment conditions, especially to the structured behavioral interventions to be studied in the community treatment clinic. Antisocial drug abusers are of special interest because they are prevalent, difficult to treat, and have elevated rates of HIV risk behavior and HIV infection. These Center assessment data will provide valuable information about the relation of individual patient characteristics to drug abuse treatment outcome, and about how best to identify and assess for treatment-relevant differences in individual patient characteristics. Overall, these Core resources and data should contribute to improvements in LAAM pharmacotherapy and in behavioral therapy, and to improved bases for patient-treatment matching.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA005273-14
Application #
6501498
Study Section
Project Start
2001-09-15
Project End
2002-06-30
Budget Start
Budget End
Support Year
14
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Peirce, Jessica M; Kindbom, Kori A; Waesche, Matthew C et al. (2008) Posttraumatic stress disorder, gender, and problem profiles in substance dependent patients. Subst Use Misuse 43:596-611
Burke, Christopher K; Peirce, Jessica M; Kidorf, Michael S et al. (2008) Sleep problems reported by patients entering opioid agonist treatment. J Subst Abuse Treat 35:328-33
Wedam, Erich F; Bigelow, George E; Johnson, Rolley E et al. (2007) QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 167:2469-75
Sigmon, Stacey C (2007) Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement. Exp Clin Psychopharmacol 15:1-20
Carroll, C Patrick; Kidorf, Michael; Strain, Eric C et al. (2007) Comparison of demographic and clinical characteristics between opioid-dependent individuals admitted to a community-based treatment setting and those enrolled in a research-based treatment setting. J Subst Abuse Treat 33:355-61
Lott, David C; Strain, Eric C; Brooner, Robert K et al. (2006) HIV risk behaviors during pharmacologic treatment for opioid dependence: a comparison of levomethadyl acetate [corrected] buprenorphine, and methadone. J Subst Abuse Treat 31:187-94
Sigmon, Stacey C; Moody, David E; Nuwayser, Elie S et al. (2006) An injection depot formulation of buprenorphine: extended bio-delivery and effects. Addiction 101:420-32
Jones, Hendree E; Fitzgerald, Heather; Johnson, Rolley E (2005) Males and females differ in response to opioid agonist medications. Am J Addict 14:223-33
Lofwall, Michelle R; Brooner, Robert K; Bigelow, George E et al. (2005) Characteristics of older opioid maintenance patients. J Subst Abuse Treat 28:265-72
Disney, Elizabeth R; Kidorf, Michael; King, Van L et al. (2005) Prevalence and correlates of cocaine physical dependence subtypes using the DSM-IV in outpatients receiving opioid agonist medication. Drug Alcohol Depend 79:23-32

Showing the most recent 10 out of 44 publications